We are a group of motivated immunologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
Our approach
We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases.
IL-2 Cancer Immunotherapy
Our first program going into clinical trials is ANV419, a selective interleukin-2 (IL-2) receptor agonist – a type of protein that can enhance a patient’s immune system in order to target and defeat tumors.
Our Immunotherapy Pipeline
Our pipeline includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.
Years of Experience
Million CHF Funding
Growing team
LATEST NEWS
10
November
2020
Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anaveon, an immuno-oncology company, today announced that it will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
26
May
2020
Anaveon Unveils Refreshed Brand Identity and Website
Anaveon, a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction, reveals a refreshed brand and website.
4 
10
April
2019
Anaveon Announces Appointment of Dr Allison Jeynes-Ellis to its Board of Directors
Anaveon, an immuno-oncology company, today announced that it has appointed Dr Allison Jeynes-Ellis to its Board of Directors.
3 
26
February
2019
Anaveon, a New Immuno-Oncology Company, Announces CHF 35 million Series A Financing
Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund.
3 
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.
About us
We are committed to developing treatments that benefit patients.
Science
We are developing an IL-2 immunotherapy for cancer.
Team
We are driven by the urgency of patients.
Investors
&
Partners
We are backed by more than 36 million CHF (€34 million) of funding.